HPaCD against Alzheimer Disease
HP-beta-cyclodextrin (HPbCD) is currently in clinical trials against Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease (AD) and these trials
A forum for researchers, students and applicants in the field of cyclodextrin technology
HP-beta-cyclodextrin (HPbCD) is currently in clinical trials against Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease (AD) and these trials
In the last year, the Cyclodextrin News reported on an oral spray containing alpha-cyclodextrin and hydroxytyrosol developed by Italian researchers
A patent application by Knut M. Wittkowski (ASDERA LLC, US) entitled “Use of cyclodextrins in diseases and disorders involving phospholipid
If you are following advances in the re-discovery of cyclodextrins as APIs, there is quite a race among the candidates